The Conversation (0)
Conatus Pharmaceuticals Significant Joint-Venture Review and Analysis of Third Quarter 2016 Results
Jan. 03, 2017 09:30AM PST
Technology Investing
Conatus Pharmaceuticals (NASDAQ:CNAT) a biotechnology company focused on treating liver disease, announced earnings for the third quarter of 2016 on November 8, 2016. They are looked at by Traders News Source, an equity research firm specializing in small and micro-cap securities. As quoted in the press release: Based on current technology (and no regulatory approval …
Conatus Pharmaceuticals (NASDAQ:CNAT) a biotechnology company focused on treating liver disease, announced earnings for the third quarter of 2016 on November 8, 2016. They are looked at by Traders News Source, an equity research firm specializing in small and micro-cap securities.
As quoted in the press release:
Based on current technology (and no regulatory approval for drugs to treat cirrhosis), patients’ eventual solution is to seek a liver transplant. Unfortunately, demand exceeds supply by an overwhelming margin. Conatus stock is up over +80% in 2016. EPS loss of ($0.31) reflects continued investment in trails of CNAT’s liver treatment products. Given the recent announcement of the firm’s joint-venture with pharmaceutical company Novartis, focus will turn from funding to progress on trials of the company’s liver disease treatment.